Skip to main content
Erschienen in: Supportive Care in Cancer 8/2004

01.08.2004 | Original Article

Differences in physician-reported practice in palliative sedation therapy

verfasst von: Tatsuya Morita

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Abstract

Background

Although palliative sedation therapy is often required in terminally ill cancer patients, little is known about actual practice. The aims of this study were to clarify the physician-reported sedation practices and the factors influencing the sedation rates.

Methods

A questionnaire was sent to 105 representative physicians of all certified palliative care units in Japan. A total of 81 responses were analyzed (effective response rate, 80%).

Results

The prevalence of continuous-deep sedation for physical symptoms was <10% in 33 institutions (41%), 10–50% in 43 institutions (53%), and >50% in 5 institutions (6.2%). The prevalence of continuous-deep sedation for psychoexistential suffering was 0% in 52 institutions (64%), 0.5–5% in 26 institutions (32%) and more than 10% in 3 institutions (3.6%). Continuous-deep sedation was more frequently performed by physicians who did not believe clear consciousness was necessary for a good death, who did not believe that sedation often shortened patient life, who worked with nurses specializing in cancer/palliative care, who judged the symptoms as refractory without actual trials of treatments, who performed continuous sedation first rather than intermittent sedation, and who used phenobarbitones frequently.

Conclusions

Physician-reported practice in palliative sedation therapy varied widely among institutions. The differences were mainly associated with the physicians’ philosophy about a good death, physicians’ belief about the effects of sedation on patient survival, and physicians’ medical practice. Discussion should be focused on these divergent areas, and clear clinical guidelines are urgently needed to provide valid end-of-life care.
Literatur
1.
Zurück zum Zitat Breitbart W, Gibson C, Tremblay A (2002) The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouse/caregivers, and their nurses. Psychosomatics 43:183–194CrossRefPubMed Breitbart W, Gibson C, Tremblay A (2002) The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouse/caregivers, and their nurses. Psychosomatics 43:183–194CrossRefPubMed
2.
Zurück zum Zitat Bruera E, Franco JJ, Maltoni M, et al (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10:287–291PubMed Bruera E, Franco JJ, Maltoni M, et al (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10:287–291PubMed
3.
Zurück zum Zitat Chater S, Viola R, Paterson J, et al (1998) Sedation for intractable distress in the dying—a survey of experts. Palliat Med 12:255–269CrossRefPubMed Chater S, Viola R, Paterson J, et al (1998) Sedation for intractable distress in the dying—a survey of experts. Palliat Med 12:255–269CrossRefPubMed
4.
Zurück zum Zitat Chiu TY, Hu WY, Lue BH, Cheng SY, Chen CY (2001) Sedation for refractory symptoms of terminal cancer patients in Taiwan. J Pain Symptom Manage 21:467–472CrossRefPubMed Chiu TY, Hu WY, Lue BH, Cheng SY, Chen CY (2001) Sedation for refractory symptoms of terminal cancer patients in Taiwan. J Pain Symptom Manage 21:467–472CrossRefPubMed
5.
Zurück zum Zitat Cowan JD, Walsh D (2001) Terminal sedation in palliative medicine: definition and review of the literature. Support Care Cancer 9:403–407CrossRefPubMed Cowan JD, Walsh D (2001) Terminal sedation in palliative medicine: definition and review of the literature. Support Care Cancer 9:403–407CrossRefPubMed
6.
Zurück zum Zitat de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378–384PubMed de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378–384PubMed
7.
Zurück zum Zitat Emanuel El, Fairclough D, Clarridge BC, et al (2000) Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med 133:527–532PubMed Emanuel El, Fairclough D, Clarridge BC, et al (2000) Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med 133:527–532PubMed
8.
Zurück zum Zitat Fainsinger RL, Waller A, Bercovici M, et al (2000) A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 14:257–265CrossRefPubMed Fainsinger RL, Waller A, Bercovici M, et al (2000) A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 14:257–265CrossRefPubMed
9.
Zurück zum Zitat Grassi L, Magnani K, Ercolani M (1999) Attitudes toward euthanasia and physician-assisted suicide among Italian primary care physicians. J Pain Symptom Manage 17:188–196CrossRefPubMed Grassi L, Magnani K, Ercolani M (1999) Attitudes toward euthanasia and physician-assisted suicide among Italian primary care physicians. J Pain Symptom Manage 17:188–196CrossRefPubMed
10.
Zurück zum Zitat Howard OM, Fairclough DL, Daniels ER, et al (1997) Physician desire for euthanasia and assisted suicide: would physicians practice what they preach? J Clin Oncol 15:428–432PubMed Howard OM, Fairclough DL, Daniels ER, et al (1997) Physician desire for euthanasia and assisted suicide: would physicians practice what they preach? J Clin Oncol 15:428–432PubMed
11.
Zurück zum Zitat Jansen LA, Sulmasy DP (2002) Sedation, alimentation, hydration, and equivocation: careful conversation about care at the end of life. Ann Intern Med 136:845–849PubMed Jansen LA, Sulmasy DP (2002) Sedation, alimentation, hydration, and equivocation: careful conversation about care at the end of life. Ann Intern Med 136:845–849PubMed
12.
Zurück zum Zitat Lawlor PG, Ganon B, Mancini IL, et al (2000) Occurrences, causes, and outcome of delirium in patients with advanced cancer. A prospective study. Arch Intern Med 160:786–794PubMed Lawlor PG, Ganon B, Mancini IL, et al (2000) Occurrences, causes, and outcome of delirium in patients with advanced cancer. A prospective study. Arch Intern Med 160:786–794PubMed
13.
Zurück zum Zitat Morita T, Tsunoda J, Inoue S, Chihara S (1999) Do hospice clinicians sedate patients intending to hasten death? J Palliat Care 15:20–23 Morita T, Tsunoda J, Inoue S, Chihara S (1999) Do hospice clinicians sedate patients intending to hasten death? J Palliat Care 15:20–23
14.
Zurück zum Zitat Morita T, Tsuneto S, Shima Y (2001) Proposed definitions for terminal sedation. Lancet 358:335–336CrossRef Morita T, Tsuneto S, Shima Y (2001) Proposed definitions for terminal sedation. Lancet 358:335–336CrossRef
15.
Zurück zum Zitat Morita T, Tsunoda J, Inoue S, et al (2001) Effects of high dose opioid and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 21:282–289CrossRefPubMed Morita T, Tsunoda J, Inoue S, et al (2001) Effects of high dose opioid and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 21:282–289CrossRefPubMed
16.
Zurück zum Zitat Morita T, Akechi T, Sugawara Y, Chihara S, Uchitomi Y (2002) Practices and attitudes of Japanese oncologists and palliative care physicians concerning terminal sedation: a nationwide survey. J Clin Oncol 20:758–764CrossRefPubMed Morita T, Akechi T, Sugawara Y, Chihara S, Uchitomi Y (2002) Practices and attitudes of Japanese oncologists and palliative care physicians concerning terminal sedation: a nationwide survey. J Clin Oncol 20:758–764CrossRefPubMed
17.
Zurück zum Zitat Morita T, Tsuneto S, Shima Y (2002) Definition of sedation for symptom relief: a systematic literature review and a proposal of operational criteria. J Pain Symptom Manage 24:447–453CrossRefPubMed Morita T, Tsuneto S, Shima Y (2002) Definition of sedation for symptom relief: a systematic literature review and a proposal of operational criteria. J Pain Symptom Manage 24:447–453CrossRefPubMed
18.
Zurück zum Zitat Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y (2004) Family-perceived distress about delirium-related symptoms of terminally ill cancer patients. Psychosomatics (in press) Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y (2004) Family-perceived distress about delirium-related symptoms of terminally ill cancer patients. Psychosomatics (in press)
19.
Zurück zum Zitat Orentlicher D (1998) Dr. Orentlicher replies. N Engl J Med 338:1230–1231CrossRef Orentlicher D (1998) Dr. Orentlicher replies. N Engl J Med 338:1230–1231CrossRef
20.
Zurück zum Zitat Peruselli C, Giulio PD, Toscani F, et al (1999) Home palliative care for terminal cancer patients: a survey on the final week of life. J Pain Symptom Manage 13:233–241CrossRef Peruselli C, Giulio PD, Toscani F, et al (1999) Home palliative care for terminal cancer patients: a survey on the final week of life. J Pain Symptom Manage 13:233–241CrossRef
21.
Zurück zum Zitat Portney RK, Coyle N, Kash KM, et al (1997) Determinants of the willingness to endorse assisted suicide. A survey of physicians, nurses, and social workers. Psychosomatics 38:277–287PubMed Portney RK, Coyle N, Kash KM, et al (1997) Determinants of the willingness to endorse assisted suicide. A survey of physicians, nurses, and social workers. Psychosomatics 38:277–287PubMed
22.
Zurück zum Zitat Quill TE, Lo B, Brock DW (1997) Palliative options of last resort: a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA 278:2099–2104CrossRefPubMed Quill TE, Lo B, Brock DW (1997) Palliative options of last resort: a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA 278:2099–2104CrossRefPubMed
23.
Zurück zum Zitat Sales JP (2001) Sedation and terminal care. Eur J Palliat Care 8:97–100 Sales JP (2001) Sedation and terminal care. Eur J Palliat Care 8:97–100
24.
Zurück zum Zitat Stone P, Phillips C, Spruyt O, et al (1997) A comparison of the use of sedatives in a hospital support team and in a hospice. Palliat Med 11:140–144PubMed Stone P, Phillips C, Spruyt O, et al (1997) A comparison of the use of sedatives in a hospital support team and in a hospice. Palliat Med 11:140–144PubMed
25.
Zurück zum Zitat Sykes N, Thorns A (2003) Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 163:341–344CrossRefPubMed Sykes N, Thorns A (2003) Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 163:341–344CrossRefPubMed
26.
Zurück zum Zitat Ventafridda V, Ripamonti C, De Connno F, et al (1990) Symptom prevalence and control during cancer patients’ last days of life. J Palliat Care 6:7–11 Ventafridda V, Ripamonti C, De Connno F, et al (1990) Symptom prevalence and control during cancer patients’ last days of life. J Palliat Care 6:7–11
Metadaten
Titel
Differences in physician-reported practice in palliative sedation therapy
verfasst von
Tatsuya Morita
Publikationsdatum
01.08.2004
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2004
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0603-8

Weitere Artikel der Ausgabe 8/2004

Supportive Care in Cancer 8/2004 Zur Ausgabe

Forthcoming Meetings

August 2004

Society News

August 2004

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.